Feb 28, 2023 | Anocca in the news
Originally published in Cell & Gene Therapy Insights Read the transcript of David McCall, Editor, BioInsights speaking to Paula Villaescusa Sánchez, Field Application Specialist, CGT, Cytiva and Anocca’s Head of GMP Process Development, Anette Brass, which...
Dec 21, 2022 | Press release
Södertälje, 21 december 2022 – Anocca, ett helt integrerat bioteknikföretag för utveckling av T-cellsbehandlingar, meddelade idag att det har säkrat 25 miljoner EUR i form av riskkapitallån från Europeiska investeringsbanken (EIB). Denna betydande investering visar på...
Dec 21, 2022 | Press release
Södertälje, Sweden, 21 December 2022 – Anocca, a fully integrated cell therapy biotechnology company, today announced that it has secured EUR 25 million Venture Debt financing from the European Investment Bank (EIB). This significant investment recognises the strength...
Apr 7, 2022 | Press release
Södertälje, Sweden, 7th April 2022 – Anocca, a biotechnology company using its precision biology platforms to engineer a broad portfolio of innovative T cell therapeutics, today announced the appointment of Dr. Michael Kalos to its Scientific Advisory Board (SAB). Dr....
Feb 22, 2022 | Press release
Södertälje, Sweden, February 22, 2022 – Anocca AB, a pioneer in T cell immunotherapy, today announces it has made a number of appointments to expand its senior leadership team and strengthen its business development and R&D capabilities. This includes the...
